News

Immunicum in labiotech!

  • 11:01

Immunicum was featured in labiotech in the article “Green light from the FDA for a Swedish Therapy Targeting… Read more

IND clearance

  • 13:29

Immunicum AB announced today that the United States Food and Drug Administration (FDA) has cleared the Company’s Investigational… Read more

Company research report in english

  • 16:05

Redeye releases a company research report of Immunicum in english. Read it here: immunicum-redeye-company-analysis-20160927

New CEO – Carlos de Sousa

  • 08:37

Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016…. Read more

Company presentation

  • 17:23

Immunicum’s CEO, Jamal El-Mosleh, holds a company presentation at Redeye Fight Cancer 2016. See the presentation here: Company… Read more

Redeye Immunicum analysis

  • 17:20

Redeye updates the company analysis of Immunicum. Read it here in Swedish: Analysis.

SITC poster presentation

  • 10:47

Society for Immunotherapy of Cancer (SITC) has accepted Immunicum’s poster containing clinical data from INTUVAX – HCC I/II… Read more

RCC I/II improved survival data

  • 10:54

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients Immunicum initiated a phase… Read more